{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:40:09Z","timestamp":1741869609714,"version":"3.38.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cpt.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:42:40Z","timestamp":1733791360000},"page":"173-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating multi-omics methods for personalized treatment of refractory chronic myelomonocytic leukemia with NRAS and TET2 mutations"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3188-7639","authenticated-orcid":false,"given":"Chuandong","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-2278","authenticated-orcid":false,"given":"XueChun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.12.001_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2024.12.001_bib2","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/cancers13071610","article-title":"Risk-adapted, individualized treatment strategies of\u00a0myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)","volume":"13","author":"Bewersdorf","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cpt.2024.12.001_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3324\/haematol.2021.279500","article-title":"How I diagnose and treat chronic myelomonocytic leukemia","volume":"107","author":"Patnaik","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.cpt.2024.12.001_bib4","doi-asserted-by":"crossref","first-page":"W411","DOI":"10.1093\/nar\/gkad412","article-title":"PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data","volume":"51","author":"Jim\u00e9nez-Santos","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cpt.2024.12.001_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/bjh.19261","article-title":"Quantitative transcriptome-based analysis predicts a combination therapy for severe haemophilia B: a case report","volume":"204","author":"Zhang","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2024.12.001_bib6","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/MBC.0000000000001095","article-title":"New developments in the diagnosis of primary immune thrombocytopenia","volume":"33","author":"Lozano","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.cpt.2024.12.001_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cpt.2024.12.001_bib8","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s12094-021-02585-x","article-title":"Mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"23","author":"Jian","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.cpt.2024.12.001_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.12.001_bib10","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2024.12.001_bib11","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1038\/s41375-020-0929-3","article-title":"Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia","volume":"34","author":"Kloos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2024.12.001_bib12","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.12.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpt.2024.09.001","article-title":"Advanced molecular diagnostics: Driving precision in hematological malignancies","author":"Bao","year":"2024","journal-title":"Cancer Pathog Ther"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224001034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224001034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:03:45Z","timestamp":1741867425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713224001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2949713224001034"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.12.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"type":"print","value":"2949-7132"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating multi-omics methods for personalized treatment of refractory chronic myelomonocytic leukemia with NRAS and TET2 mutations","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}